<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075074</url>
  </required_header>
  <id_info>
    <org_study_id>STU00023475</org_study_id>
    <nct_id>NCT01075074</nct_id>
  </id_info>
  <brief_title>Pre Operative Transversus Abdominis Plane Block Laparoscopic Gynecological Surgery</brief_title>
  <official_title>The Effect of Pre Operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Outpatient Laparoscopic Gynecological Surgery: A Prospective, Randomized Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of pre-operative transversus abdominis plane block will reduce pain after outpatient
      laparoscopic gynecological surgery and improve quality of recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      75 subjects will be randomly allocated into 3 groups, using a computer generated table of
      random numbers. Group A (study group) will receive a bilateral TAP block using 15 cc of 0.5%
      ropivacaine on each side. Group B (control group) will receive 15 cc of sterile normal
      saline. Group C (study group 2) will receive a bilateral TAP block using 15 cc of 0.25%
      ropivacaine on each side.

      Subjects will be premedicated with intravenous (IV) midazolam 0.04 mg/kg. Routine ASA
      monitors will be applied. Anesthesia will be induced with remifentanil infusion started at
      0.1 mcg/kg/minute titrated to keep blood pressure within 20% of the baseline and propofol 1.0
      -2.0 mg/kg. Tracheal intubation will be facilitated with rocuronium (0.6 mg/kg) or
      succinylcholine (1-2mg /kg). After induction, a bilateral TAP block will be performed in both
      groups, under ultrasound guidance with a transportable ultrasound device (SonoSite, Bothell,
      WA, USA) and a linear 6-13 MHz ultrasound transducer .Once the EOAM, IOAM and TAM are
      visualized at the level of the anterior axillary line between the 12th rib and the iliac
      crest, the puncture area and the ultrasound probe will be prepared in a sterile manner. Then
      the block will be performed with a 21 G 90mm StimuQuik needle( Arrow International, Reading,
      PA, USA ) utilizing an &quot;in- plane&quot; ultrasound-guided technique by three investigators (GDO
      ,AP). Once the tip of the needle is placed in the space between the IOAM and TAM, and after
      negative aspiration of blood, 15 cc of 0.5% ropivacaine, 15 cc of 0.25% ropivacaine or
      sterile normal saline will be administered under direct ultrasonographic guidance. The
      contralateral block will be performed in the same fashion. Anesthesia will be maintained with
      sevoflurane titrated to maintain a bispectral index (BIS) between 40-60 , remifentanil
      infusion started at 0.1mcg/kg/min titrated to keep blood pressure within 20 % of baseline
      values , and rocuronium that will be administered at the discretion of the anesthesiologist.
      Upon termination of the surgery, neuromuscular blockade will be antagonized with a
      combination of neostigmine 0.05mg/kg and glycopyrrolate 0.01 mg/kg. Subjects will also
      receive ketorolac 30 mg IV after discontinuation of remifentanil for postoperative pain
      control. Ondansetron 4 mg IV will be administered to prevent postoperative nausea and
      vomiting. Subjects will be assessed in the OR after extubation for their pain using a
      numerical rating scale and if pain greater than 4/10 they will receive hydromorphone(10 mcg
      /kg IV) Subjects will receive IV Hydromorphone in divided doses as needed to achieve a verbal
      rating score for pain &lt;4 out of 10 In PACU.They will also receive metoclopramide (20 mg IV )
      as rescue antiemetic in PACU. The primary and secondary outcomes will be assessed by an
      independent observer who will be blinded to group allocation (CA, AP, SA, YV, RJM and PF). A
      study team representative will telephone the participant at 24 hours, to complete the
      modified quality of recovery (QOR40) survey and ask the following:

        1. How much pain they are experiencing 0-10

        2. How and what kind of pain medications have been used since discharge.

        3. If they have had any nausea

        4. What kind of nausea relief medications have been used since discharge
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Quality of Recovery Questionnaire (QoR40) on the Day (24 Hours) After Surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The quality of recovery questionnaire (QOR40) is a 40 question assessment of patient recovery following surgery. It evaluates 5 domains of recovery: pain, emotional status, physical comfort, physical independence, and support. Each question is scores on a 1 to 5 Likert scale with total scores ranging for 40, representing poor recovery, to 200, representing outstanding recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Burden During Early Recovery From Anesthesia</measure>
    <time_frame>Post Operative</time_frame>
    <description>Area under the numeric rating scale for pain versus time (min) curve during the post anesthesia care admission. Numeric rating scale 0 to 10 with 0 equals no pain and 10 equals worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Pain Medications Consumed During the First 24 Hours Post Surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Opioid consumption in oral morphine equivalents taken by the subject for pain during the first 24 hours post hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge Readiness</measure>
    <time_frame>24 hours</time_frame>
    <description>Elapsed time from post anesthesia care unit to readiness to hospital discharge. Assessment were made using the modified post anesthetic discharge scoring system. This assess 5 criteria: vital signs, activity and mental status, pain nausea and/or vomiting, surgical bleed, and intake and output. A score greater than or equal to 9 (on a 0 to 10 scale) is considered ready for discharge.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pain</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Ropivacaine 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine 0.25%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus abdominis plane block</intervention_name>
    <description>A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.</description>
    <arm_group_label>Ropivacaine 0.05%</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>Ropivacaine 0.25%</arm_group_label>
    <other_name>TAP block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-64 years

          -  Surgery: Outpatient Gynecological laparoscopic surgery

          -  ASA status: I and II

          -  Fluent in English

        Exclusion Criteria:

          -  History of allergy to local anesthetics

          -  History of chronic opioid use

          -  Pregnant patients

          -  BMI greater than 30

        Drop-out criteria:

          -  Patient or surgeon request

          -  Complications related to the procedure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio DeOliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lovatsis D, José JB, Tufman A, Drutz HP, Murphy K. Assessment of patient satisfaction with postoperative pain management after ambulatory gynaecologic laparoscopy. J Obstet Gynaecol Can. 2007 Aug;29(8):664-7.</citation>
    <PMID>17714620</PMID>
  </reference>
  <reference>
    <citation>Wills VL, Hunt DR. Pain after laparoscopic cholecystectomy. Br J Surg. 2000 Mar;87(3):273-84. Review.</citation>
    <PMID>10718794</PMID>
  </reference>
  <reference>
    <citation>Goldstein A, Grimault P, Henique A, Keller M, Fortin A, Darai E. Preventing postoperative pain by local anesthetic instillation after laparoscopic gynecologic surgery: a placebo-controlled comparison of bupivacaine and ropivacaine. Anesth Analg. 2000 Aug;91(2):403-7.</citation>
    <PMID>10910857</PMID>
  </reference>
  <reference>
    <citation>Shaw IC, Stevens J, Krishnamurthy S. The influence of intraperitoneal bupivacaine on pain following major laparoscopic gynaecological procedures. Anaesthesia. 2001 Nov;56(11):1041-4.</citation>
    <PMID>11703235</PMID>
  </reference>
  <reference>
    <citation>Møiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A qualitative systematic review of incisional local anaesthesia for postoperative pain relief after abdominal operations. Br J Anaesth. 1998 Sep;81(3):377-83.</citation>
    <PMID>9861124</PMID>
  </reference>
  <reference>
    <citation>Keita H, Benifla JL, Le Bouar V, Porcher R, Wachowska B, Bedairia K, Mantz J, Desmonts JM. Prophylactic ip injection of bupivacaine and/or morphine does not improve postoperative analgesia after laparoscopic gynecologic surgery. Can J Anaesth. 2003 Apr;50(4):362-7.</citation>
    <PMID>12670813</PMID>
  </reference>
  <reference>
    <citation>Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009 Oct;22(5):588-93. doi: 10.1097/ACO.0b013e328330373a. Review.</citation>
    <PMID>19606021</PMID>
  </reference>
  <reference>
    <citation>Turner GA, Chalkiadis G. Comparison of preoperative with postoperative lignocaine infiltration on postoperative analgesic requirements. Br J Anaesth. 1994 May;72(5):541-3.</citation>
    <PMID>8198905</PMID>
  </reference>
  <reference>
    <citation>O'Donnell BD, McDonnell JG, McShane AJ. The transversus abdominis plane (TAP) block in open retropubic prostatectomy. Reg Anesth Pain Med. 2006 Jan-Feb;31(1):91. Erratum in: Reg Anesth Pain Med. 2006 May-Jun;31(3):286. McDonnell, John G [added]; McShane, Alan J [added].</citation>
    <PMID>16418039</PMID>
  </reference>
  <reference>
    <citation>Hebbard P, Fujiwara Y, Shibata Y, Royse C. Ultrasound-guided transversus abdominis plane (TAP) block. Anaesth Intensive Care. 2007 Aug;35(4):616-7.</citation>
    <PMID>18020088</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>March 6, 2012</results_first_submitted>
  <results_first_submitted_qc>March 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2012</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>TAP block</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Gynecologic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from Prentice Women's Hospital consecutively from 04/01/2010-02/2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine 0.05%</title>
          <description>Subjects received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Subjects received a transversus abdominis plane block using 15 cc of sterile normal saline</description>
        </group>
        <group group_id="P3">
          <title>Ropivacaine 0.25%</title>
          <description>Subjects received a bilateral transversus abdominis plane block using 15cc of ropivacaine 0.025%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Surgeon changed to open incisional case</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine 0.05%</title>
          <description>Subjects received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Subjects received a transversus abdominis plane block using 15 cc of sterile normal saline</description>
        </group>
        <group group_id="B3">
          <title>Ropivacaine 0.25%</title>
          <description>Subjects received a bilateral transversus abdominis plane block using 15cc of ropivacaine 0.025%</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="8"/>
                    <measurement group_id="B2" value="38" spread="10"/>
                    <measurement group_id="B3" value="35" spread="9"/>
                    <measurement group_id="B4" value="37" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Quality of Recovery Questionnaire (QoR40) on the Day (24 Hours) After Surgery</title>
        <description>The quality of recovery questionnaire (QOR40) is a 40 question assessment of patient recovery following surgery. It evaluates 5 domains of recovery: pain, emotional status, physical comfort, physical independence, and support. Each question is scores on a 1 to 5 Likert scale with total scores ranging for 40, representing poor recovery, to 200, representing outstanding recovery.</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.5%</title>
            <description>The ropivacaine 0.5% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.5% ropivacaine on each side</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>The control group will receive a bilateral transversus abdominal plane block using 15 cc of sterile normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 0.25%</title>
            <description>The ropivacaine 0.25% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.25% ropivacaine on each side</description>
          </group>
        </group_list>
        <measure>
          <title>The Quality of Recovery Questionnaire (QoR40) on the Day (24 Hours) After Surgery</title>
          <description>The quality of recovery questionnaire (QOR40) is a 40 question assessment of patient recovery following surgery. It evaluates 5 domains of recovery: pain, emotional status, physical comfort, physical independence, and support. Each question is scores on a 1 to 5 Likert scale with total scores ranging for 40, representing poor recovery, to 200, representing outstanding recovery.</description>
          <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" lower_limit="160" upper_limit="190"/>
                    <measurement group_id="O2" value="157" lower_limit="148" upper_limit="169"/>
                    <measurement group_id="O3" value="173" lower_limit="165" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A sample size of 23 subjects per group was estimated to achieve 80% power to detect a 10 point difference in the aggregated QOR40 score for the 3 study groups to be compared assuming an overall standard deviation of 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Corrected for 6 comparisons.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Burden During Early Recovery From Anesthesia</title>
        <description>Area under the numeric rating scale for pain versus time (min) curve during the post anesthesia care admission. Numeric rating scale 0 to 10 with 0 equals no pain and 10 equals worst pain imaginable.</description>
        <time_frame>Post Operative</time_frame>
        <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.5%</title>
            <description>The ropivacaine 0.5% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.5% ropivacaine on each side</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>The normal saline group will receive a bilateral transversus abdominal plane block using 15 cc of sterile normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 0.25%</title>
            <description>The ropivacaine 0.25% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.25% ropivacaine on each side</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Burden During Early Recovery From Anesthesia</title>
          <description>Area under the numeric rating scale for pain versus time (min) curve during the post anesthesia care admission. Numeric rating scale 0 to 10 with 0 equals no pain and 10 equals worst pain imaginable.</description>
          <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
          <units>score on a scale * minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210" spread="4" lower_limit="90" upper_limit="345"/>
                    <measurement group_id="O2" value="405" spread="4" lower_limit="360" upper_limit="502"/>
                    <measurement group_id="O3" value="210" spread="4" lower_limit="135" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P values is corrected for 6 comparisons</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Corrected for 6 comparisons</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>195</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98</ci_lower_limit>
            <ci_upper_limit>300</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>195</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98</ci_lower_limit>
            <ci_upper_limit>278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-105</ci_lower_limit>
            <ci_upper_limit>83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Pain Medications Consumed During the First 24 Hours Post Surgery</title>
        <description>Opioid consumption in oral morphine equivalents taken by the subject for pain during the first 24 hours post hospital discharge</description>
        <time_frame>24 hours</time_frame>
        <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.5%</title>
            <description>Ropivacaine 0.5% group will receive a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal saline group will receive a bilateral transversus abdominis plane block 15 cc of sterile normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 0.25%</title>
            <description>Ropivicaine 0.25% group will receive a bilateral transversus abdominis plane block using 15 cc of 0.25% ropivacaine on each side</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Pain Medications Consumed During the First 24 Hours Post Surgery</title>
          <description>Opioid consumption in oral morphine equivalents taken by the subject for pain during the first 24 hours post hospital discharge</description>
          <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
          <units>mEq of PO morphine equivalent</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="13" upper_limit="72"/>
                    <measurement group_id="O2" value="78" lower_limit="61" upper_limit="90"/>
                    <measurement group_id="O3" value="39" lower_limit="25" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Corrected for multiple comparisons (n=6).</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8</ci_lower_limit>
            <ci_upper_limit>50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge Readiness</title>
        <description>Elapsed time from post anesthesia care unit to readiness to hospital discharge. Assessment were made using the modified post anesthetic discharge scoring system. This assess 5 criteria: vital signs, activity and mental status, pain nausea and/or vomiting, surgical bleed, and intake and output. A score greater than or equal to 9 (on a 0 to 10 scale) is considered ready for discharge.</description>
        <time_frame>24 hours</time_frame>
        <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.5%</title>
            <description>The ropivacaine 0.5% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.5% ropivacaine on each side</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>The control group will receive a bilateral transversus abdominal plane block using 15 cc of sterile normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 0.25%</title>
            <description>The ropivacaine 0.25% group will receive a bilateral transversus abdominal plane block using 15 cc of 0.25% ropivacaine on each side</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge Readiness</title>
          <description>Elapsed time from post anesthesia care unit to readiness to hospital discharge. Assessment were made using the modified post anesthetic discharge scoring system. This assess 5 criteria: vital signs, activity and mental status, pain nausea and/or vomiting, surgical bleed, and intake and output. A score greater than or equal to 9 (on a 0 to 10 scale) is considered ready for discharge.</description>
          <population>75 subjects were randomized in 3 groups of 25, 5 were excluded from analysis because the surgeon had to proceed to an open incision from a laparoscopic case during the procedure.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="75" upper_limit="120"/>
                    <measurement group_id="O2" value="120" lower_limit="105" upper_limit="150"/>
                    <measurement group_id="O3" value="90" lower_limit="75" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>Corrected for multiple comparisons (n=6).</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post anesthesia care unit until discharge</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine 0.5%</title>
          <description>Subjects received a bilateral transversus abdominis plane block using 15 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.</description>
        </group>
        <group group_id="E3">
          <title>Ropivacaine 0.25%</title>
          <description>Subjects received a bilateral transversus abdominis plane block using 15cc of ropivicaine 0.25%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not obtain local anesthetic levels to compare safety profile. We were underpowered to detect a difference in the physical comfort dimension of the QOR questionnaire between the ropivacaine groups and the saline group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-926-8373</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

